Arcus Biosciences annual shareholders’ equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Shareholders’ Equity Growth & History (RCUS)
Arcus Biosciences's shareholders’ equity was $631.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $631.0M | $146.0M | +30.10% |
| 2024 | 2024-12-31 | $485.0M | $23.0M | +4.98% |
| 2023 | 2023-12-31 | $462.0M | −$195.0M | −29.68% |
| 2022 | 2022-12-31 | $657.0M | −$185.0M | −21.97% |
| 2021 | 2021-12-31 | $842.0M | $340.0M | +67.73% |
| 2020 | 2020-12-31 | $502.0M | $338.0M | +206.10% |
| 2019 | 2019-12-31 | $164.0M | −$70.9M | −30.20% |
| 2018 | 2018-12-31 | $234.9M | $307.3M | — |
| 2017 | 2017-12-31 | −$72.3M | −$52.3M | — |
| 2016 | 2016-12-31 | −$20.0M | — | — |
Arcus Biosciences quarterly shareholders’ equity
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $464.0M | −$85.0M | −15.48% |
| Q1 2026 | 2026-03-31 | $524.0M | −$7.0M | −1.32% |
| Q4 2025 | 2025-12-31 | $631.0M | $146.0M | +30.10% |
| Q3 2025 | 2025-09-30 | $436.0M | −$129.0M | −22.83% |
| Q2 2025 | 2025-06-30 | $549.0M | −$86.0M | −13.54% |
| Q1 2025 | 2025-03-31 | $531.0M | −$176.0M | −24.89% |
| Q4 2024 | 2024-12-31 | $485.0M | $23.0M | +4.98% |
| Q3 2024 | 2024-09-30 | $565.0M | $45.0M | +8.65% |
| Q2 2024 | 2024-06-30 | $635.0M | $69.0M | +12.19% |
| Q1 2024 | 2024-03-31 | $707.0M | $107.0M | +17.83% |
| Q4 2023 | 2023-12-31 | $462.0M | −$195.0M | −29.68% |
| Q3 2023 | 2023-09-30 | $520.0M | −$179.0M | −25.61% |
| Q2 2023 | 2023-06-30 | $566.0M | −$181.0M | −24.23% |
| Q1 2023 | 2023-03-31 | $600.0M | −$197.0M | −24.72% |
| Q4 2022 | 2022-12-31 | $657.0M | −$185.0M | −21.97% |
| Q3 2022 | 2022-09-30 | $699.0M | $156.4M | +28.82% |
| Q2 2022 | 2022-06-30 | $747.0M | $142.4M | +23.56% |
| Q1 2022 | 2022-03-31 | $797.0M | $132.2M | +19.89% |
| Q4 2021 | 2021-12-31 | $842.0M | $340.0M | +67.73% |
| Q3 2021 | 2021-09-30 | $542.6M | −$1.8M | −0.33% |
| Q2 2021 | 2021-06-30 | $604.6M | $175.8M | +41.02% |
| Q1 2021 | 2021-03-31 | $664.8M | $524.2M | +372.70% |
| Q4 2020 | 2020-12-31 | $502.0M | $338.0M | +206.10% |
| Q3 2020 | 2020-09-30 | $544.4M | $367.2M | +207.19% |
| Q2 2020 | 2020-06-30 | $428.7M | $232.1M | +118.01% |
| Q1 2020 | 2020-03-31 | $140.6M | −$80.9M | −36.53% |
| Q4 2019 | 2019-12-31 | $164.0M | −$70.9M | −30.20% |
| Q3 2019 | 2019-09-30 | $177.2M | −$67.9M | −27.70% |
| Q2 2019 | 2019-06-30 | $196.6M | −$57.9M | −22.75% |
| Q1 2019 | 2019-03-31 | $221.6M | −$45.0M | −16.89% |
| Q4 2018 | 2018-12-31 | $234.9M | $307.3M | — |
| Q3 2018 | 2018-09-30 | $245.1M | — | — |
| Q2 2018 | 2018-06-30 | $254.6M | — | — |
| Q1 2018 | 2018-03-31 | $266.6M | — | — |
| Q4 2017 | 2017-12-31 | −$72.3M | — | — |
Arcus Biosciences shareholders’ equity trends
Over the last five fiscal years, Arcus Biosciences's shareholders’ equity increased from $502.0M to $631.0M, a change of $129.0M. The latest reported quarter, Q2 2026, shows $464.0M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
